ISRGISRG
US • —
$397.68
P/E
48.24
PEG
2.31
FCF Yield
—
Rev Growth YoY
+21.4% YoY
Gross Margin
66.3%
Health Score
8/10
D/E Ratio
—
Confidence
LOW
Business Snapshot
Intuitive Surgical is a pioneer in robotic-assisted surgery, primarily generating revenue from its da Vinci surgical systems, accompanying instruments and accessories, and related services. The company operates in the highly specialized medical device market, holding a dominant leadership position within robotic-assisted surgery with a significant installed base globally. As a large-cap company, it commands substantial financial scale, though its exact market capitalisation and TTM revenue are not provided in this data set. A critical defining characteristic is its entrenched ecosystem, where high switching costs and a recurring revenue model from instruments and services create a durable competitive moat.
Financial Health
Intuitive Surgical demonstrates excellent profitability with a gross margin of 66.3% and a high net margin of 28.1%. The balance sheet is exceptionally conservative, featuring a debt/equity ratio of 0.0x and exceptional short-term liquidity with a current ratio of 4.87x, indicating a fortress-like financial position with no debt...
Risk Assessment
- VALUATION — P/E ratio of 48.24x trades at more than double the sector average of 22x, embedding high expectations for future growth.
- EARNINGS QUALITY — While the company beat estimates in 4 out of 4 recent quarters, earnings growth of 20.9% is a positive indicator, not a risk.
- TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed.
- FCF / CASH BURN — Free cash flow data is not available, preventing a complete assessment of cash generation versus reported earnings.
- INSIDER — Insiders have sold shares in 6 transactions against 0 buys over the last 90 days, a net sell signal that warrants monitoring....
Intuitive Surgical demonstrates excellent profitability with a gross margin of 66.3% and a high net margin of 28.1%. The balance sheet is exceptionally conservative, featuring a debt/equity ratio of 0.0x and exceptional short-term liquidity with a current ratio of 4.87x, indicating a fortress-like financial position with no debt. Return on equity is strong at 17.0%, showcasing effective capital allocation. Overall, this pristine financial health provides immense capacity for internal reinvestment in R&D and potential strategic initiatives, with no risk of financial distress or dilution.
- VALUATION — P/E ratio of 48.24x trades at more than double the sector average of 22x, embedding high expectations for future growth. - EARNINGS QUALITY — While the company beat estimates in 4 out of 4 recent quarters, earnings growth of 20.9% is a positive indicator, not a risk. - TECHNICALS — RSI, MACD, and moving average data unavailable for this period; momentum cannot be independently confirmed. - FCF / CASH BURN — Free cash flow data is not available, preventing a complete assessment of cash generation versus reported earnings. - INSIDER — Insiders have sold shares in 6 transactions against 0 buys over the last 90 days, a net sell signal that warrants monitoring.
Unlock the full AI report
Full 8-section analysis includes:
Metric deep-dives